Immunogen Inc. (IMGN) announced Friday morning that Roche has announced positive results from its trastuzumab emtansine EMILIA Phase III trial. Trastuzumab emtansine consists of ImmunoGen's cancer-killing agent, DM1, attached to the HER2-targeting antibody, trastuzumab, and is in global development by Roche under an agreement between ImmunoGen and Genentech.
Immunogen has gapped open sharply higher Friday and is now up 1.76 at $15.50 on above average volume. The stock is now challenging the highs of the year, trading at an 8-month high.
by RTT Staff Writer
For comments and feedback: email@example.com